en
Scientific article
Review
French

Suivi au moyen-terme des patients faisant l’objet d’un traitement par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Other title[Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]
Published inBulletin du cancer, vol. 108, no. 12S, p. S65-S71
Publication date2021-12
First online date2021-03-04
Abstract

Chimeric antigen receptor (CAR) T cells are a new class of anti-cancer therapy that involves manipulating autologous or allogeneic T cells to express a CAR directed against a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) has marketing authorization for the treatment of relapsed / refractory acute lymphoblastic leukemia (ALL) in children and young adults, in addition to the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL); the marketing authorization for axicabtagene ciloleucel (Yescarta™) is for the treatment of relapsed / refractory high-grade B-cell lymphoma and for the treatment of primary mediastinal B-cell lymphoma. Both cell products are genetically modified autologous T cells directed against CD19. These recommendations, drawn up by a working group of the Francophone Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC) relate to the management of patients and the supply chain: medium-term complications, in particular cytopenias and B-cell aplasia, nursing and psychological supportive care. In another work, we will address long-term monitoring, post-marketing authorization pharmacovigilance and issues relating to JACIE and regulatory authorities. These recommendations are not prescriptive; their aim is to provide guidelines for the use of this new therapeutic approach. The purpose of this workshop is to outline the organizational aspects of this new therapeutic approach.

eng
Keywords
  • CAR-T
  • CRS
  • Cytopénies retardées
  • Delayed cytopenias
  • ICANS
  • Medium-term
  • Moyen-terme
  • SFGM-TC
  • Antibiotic Prophylaxis
  • Antigens, CD19 / immunology
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use
  • Biological Products / adverse effects
  • Biological Products / therapeutic use
  • Follow-Up Studies
  • Graft vs Host Disease / immunology
  • Humans
  • Immunotherapy, Adoptive / adverse effects
  • Immunotherapy, Adoptive / methods
  • Infections
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Lymphopenia / immunology
  • Neutropenia / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Receptors, Antigen, T-Cell / therapeutic use
  • Receptors, Chimeric Antigen
  • Societies, Medical
  • T-Lymphocytes / transplantation
  • Time Factors
Citation (ISO format)
ALSULIMAN, Tamim et al. Suivi au moyen-terme des patients faisant l’objet d’un traitement par CAR-T cells : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). In: Bulletin du cancer, 2021, vol. 108, n° 12S, p. S65–S71. doi: 10.1016/j.bulcan.2020.11.015
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0007-4551
128views
0downloads

Technical informations

Creation03/22/2022 4:58:00 PM
First validation03/22/2022 4:58:00 PM
Update time03/16/2023 7:46:16 AM
Status update03/16/2023 7:46:15 AM
Last indexation02/01/2024 8:54:34 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack